Mechanism of Action
Intracellular DNA/RNA Binding
Buforin II penetrates bacterial membranes via a transient toroidal pore mechanism facilitated by its proline hinge region. Once inside, it binds DNA and RNA with high affinity, inhibiting replication and transcription. This cell-penetrating mechanism is distinct from membrane-lytic AMPs and reduces the likelihood of resistance development through membrane adaptation.
Structural Features
The proline hinge at position 11 is critical for membrane translocation. Substitution of proline to alanine converts Buforin II to a membrane-lytic peptide similar to magainin, demonstrating the pivotal role of this residue. The N-terminal helix facilitates membrane binding while the C-terminal helix promotes DNA binding.
Research Summary
Broad-Spectrum Antimicrobial Activity
PreclinicalBuforin II shows potent activity against E. coli, S. aureus, C. albicans, and even some viruses at MIC values of 0.5-2 ug/mL. Critically, resistance development is markedly slower than with conventional antibiotics or membrane-lytic AMPs in serial passage experiments, supporting its therapeutic potential.
Anticancer Applications
PreclinicalBuforin IIb, a modified analog with enhanced cancer cell binding, selectively kills leukemia, lung, breast, and stomach cancer cells at concentrations that spare normal cells. The selectivity is attributed to binding of gangliosides overexpressed on cancer cell surfaces, triggering apoptotic pathways.
Calculate your Buforin II dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial (in vitro) | 0.5-4 ug/mL MIC | Single treatment | Direct application |
| Cancer cell selectivity | 5-20 uM (in vitro) | Single treatment | Direct application |
No human research protocols established. All values from preclinical models.
Interactions
Safety Profile
Low hemolytic activity is a key advantage over membrane-lytic AMPs. Selective translocation into bacteria with minimal mammalian cell membrane disruption at therapeutic concentrations. No human clinical data available. Proteolytic instability limits systemic use without chemical modification.
References
- [1]Park CB, et al. (2000). Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability. Proc Natl Acad Sci USA, 97(15), 8245-8250.
- [2]Cho JH, et al. (2009). Buforin IIb, a modified version of buforin II, shows anticancer activity against human tumor cells. Peptides, 30(4), 668-673.